Validation Study of the EMILY AI Device in Acute and Chronic Respiratory Failure
Functional, Clinical, and Predictive Validation Study of the EMILY AI Device in Patients With Acute and Chronic Respiratory Failure
Aether Tech S.L.
20 participants
Apr 23, 2025
INTERVENTIONAL
Conditions
Summary
Currently, there is no holistic solution for patients with respiratory diseases that includes oxygenation and management of a patient with respiratory disease, combining dynamic and automatic O2 administration and the detection of clinical worsening, generating a diagnostic suspicion, a management proposal, and notifying the medical team. For device validation, prospective studies will be conducted in patients in respiratory intermediate care units, conventional hospitalization, during physical activity in the hospital setting, and in an out-of-hospital setting. The device will be evaluated in terms of oxygenation efficacy, response time, patient safety, efficiency, versatility, clinical benefit, and adaptability.
Eligibility
Inclusion Criteria3
- Men and women over 18 years of age.
- Admitted to intermediate respiratory care unit with a diagnosis of acute respiratory failure for at least 8 hours.
- Informed consent understood and signed.
Exclusion Criteria5
- Hemodynamic instability.
- Severe temperature changes.
- Hemoglobinopathies, severe anemia, severe acidosis, or severe alkalosis.
- Anatomical disturbances.
- Pregnancy or breastfeeding.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
EMILY.AI is composed of an O2 regulating valve together with an intelligent system which allows the automation in the regulation of O2 and its customization.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06952816